BioSpace News Archive

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio, Inc. and NantKwest, Inc.

Nascent Biotech, Inc. announces that the Company is in the process of making significant additions to its core team in order to prepare for the initiation of key Phase One clinical trials to study the safety and efficacy of the Company’s flagship drug, Pritumumab, a monoclonal antibody, for the treatment of Brain Cancer.

Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that a poster detailing the trial design of a Phase 1b study of CB-280, the company’s arginase inhibitor, is being presented today at the North American Cystic Fibrosis (NACFC) 2020 Virtual Conference.

Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by PTC Therapeutics, Inc. as a limited distribution partner for EMFLAZA® (deflazacort).

Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, announces the launch of three novel IVD IHC antibody markers at the forefront of clinical diagnostic and research applications.

Foldax®, a company reinventing every aspect of the heart valve from material to design to manufacturing, today announced key additions to its Scientific and Medical Advisory Boards who will contribute to the continued development of the Tria™ LifePolymer™ heart valve technology

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the third quarter of 2020 after the close of market on Monday, November 2, 2020.

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported preliminary, unaudited net product revenue for the third quarter ended September 30, 2020.

Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced the appointment of George G. Montgomery to its board of directors.

Researchers at MINES ParisTech, one of France’s most prestigious engineering schools, have implemented Panasas® ActiveStor® high-performance computing (HPC) data storage to support the rapidly growing research efforts at the university’s Materials Research Center.